NPM1 p.W288Cfs*12
About
Gene context: NPM1
Biomarker Type: Somatic Variant
Present: True
Chromosome: 5
Start Position: 171410544
End Position: 171410543
Reference Allele: -
Alternate Allele: TCTG
Cdna Change: c.860_863dup
Protein Change: p.W288Cfs*12
Variant Annotation: Frameshift
Exon: 11/11
Rsid: rs587776806
Hgvsg: 5:g.171410540_171410543dup
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | NPM1 p.W288Cfs*12 | Acute Myeloid Leukemia | Ziftomenib | |
| FDA (1) | NPM1 p.W288Cfs*12 | Acute Myeloid Leukemia | Revumenib | |
| FDA (1) | NPM1 p.W288Cfs*12 | Acute Lymphoid Leukemia | Revumenib | |
| FDA (1) | NPM1 p.W288Cfs*12 | Burkitt Lymphoma | Revumenib | |
| FDA (1) | NPM1 p.W288Cfs*12 | Acute Leukemias of Ambiguous Lineage | Revumenib |